Dimerix Ltd is an Australian clinical-stage biopharmaceutical company that develops treatments for inflammatory and kidney-related diseases. Its main programme focuses on a chemokine receptor blocker being studied for a rare kidney disorder that damages the filtering units of the kidneys. The company works with clinical investigators and specialist kidney centres to run its trials, and it is based in Australia. Its work centres on medicines for patients with serious kidney conditions and related inflammation.
On this site Dimerix Ltd appears as a stock on the Australian Securities Exchange (Australia), code DXB, with prices in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Weak price profile
Ranks #1347 of 1815 on the Australian Securities Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Australia yet.
TrendWeak
25/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average-31.5%
From 52-week high-66.4%
MomentumWeak
21/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-16.0%
6-month return-46.2%
12-month, skipping last month-54.3%
Stability (higher is calmer)Weak
28/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)85.3%
Worst drawdown, 1 year (smaller is calmer)-73.6%
LiquidityFair
70/100
Moderate trading activity.
See the numbers →
Avg daily value traded0.25M AUD
Zero-volume days3.3%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Australia when fundamentals data for this market is added. All Australia stocks.
52-wk range 0.158 – 0.665Daily closes, split-adjusted
Signals
50-day average0.254
200-day average0.306
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.014
Technical summary
Daily
Strongly bearish
1 bullish · 3 neutral · 12 bearish
Weekly
Strongly bearish
0 bullish · 1 neutral · 11 bearish
Monthly
Strongly bearish
0 bullish · 1 neutral · 7 bearish
Moving averages (daily)
SMA 10
0.21
Bearish
EMA 10
0.21
Bearish
SMA 20
0.22
Bearish
EMA 20
0.22
Bearish
SMA 50
0.25
Bearish
EMA 50
0.24
Bearish
SMA 100
0.24
Bearish
EMA 100
0.26
Bearish
SMA 200
0.31
Bearish
EMA 200
0.30
Bearish
Oscillators (daily)
RSI (14)
37.39
Neutral
MACD (12, 26)
-0.01
Bearish
Momentum (12)
-10.64
Bearish
Stochastic %K (14)
30.00
Neutral
Williams %R (14)
-70.00
Neutral
CCI (20)
-130.6
Bullish
Pivot points (classic, last session)
S3
0.19
S2
0.19
S1
0.20
Pivot
0.21
R1
0.22
R2
0.22
R3
0.23
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in AUD. Educational only, not financial advice.
